Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

1.12USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$1.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
51,888
52-wk High
$8.20
52-wk Low
$1.09

Latest Key Developments (Source: Significant Developments)

Heat Biologics Files For Offering Of Up To $15 Mln Of Its Common Stock
Friday, 30 Mar 2018 06:34am EDT 

March 30 (Reuters) - Heat Biologics Inc ::FILES FOR OFFERING OF UP TO $15 MILLION OF ITS COMMON STOCK - SEC FILING.  Full Article

Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1
Wednesday, 28 Feb 2018 07:04am EST 

Feb 28 (Reuters) - Bristol-Myers Squibb Co ::HEAT BIOLOGICS - INTERIM RESULTS FROM PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BRISTOL-MYERS'S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB.HEAT BIOLOGICS SAYS COMBINATION OF HS-110 AND NIVOLUMAB WAS WELL TOLERATED - SEC FILING.HEAT BIOLOGICS - IN PHASE 2 CLINICAL TRIAL OF HS-110 AND NIVOLUMAB, OVERALL RESPONSES APPEARED DURABLE AND LONG LASTING‍​.  Full Article

Heat Biologics Gets Recommendation To Continue Patient Enrollment Of Ongoing Phase 2 Clinical Trial
Tuesday, 20 Feb 2018 01:59pm EST 

Feb 20 (Reuters) - Heat Biologics Inc ::SAYS GOT INDEPENDENT DMC RECOMMENDATION TO CONTINUE PATIENT ENROLLMENT OF ONGOING PHASE 2 CLINICAL TRIAL FOR HS-110 AND NIVOLUMAB​.  Full Article

Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial
Thursday, 7 Dec 2017 07:15am EST 

Dec 7 (Reuters) - Heat Biologics Inc ::SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL.HEAT BIOLOGICS - RECEIVED WRITTEN RESPONSES FROM U.S. FDA REGARDING HS-110 TRIAL DESIGN FOR TREATMENT OF NON-SMALL CELL LUNG CANCER.HEAT BIOLOGICS - FDA AGREED THAT TRIAL DESIGNS, BOTH SINGLE-ARM AND CONTROLLED, WOULD BE APPROPRIATE TO SUPPORT REGISTRATIONAL TRIAL OF HS-110.HEAT BIOLOGICS - TRIAL DESIGN DETAILS AND NEXT STEPS EXPECTED TO BE ANNOUNCED FOLLOWING READ-OUT OF PHASE 2 DATA, ANTICIPATED IN 2H 2018.  Full Article

Heat Biologics reports Q3 net loss attributable to Heat $0.06 per basic and diluted share‍​
Monday, 13 Nov 2017 07:12am EST 

Nov 13 (Reuters) - Heat Biologics Inc :Heat Biologics Inc - qtrly net loss attributable to Heat for the third quarter of 2017 was $0.06 per basic and diluted share‍​.Heat Biologics Inc - ‍cash and cash equivalents totaled approximately $4.3 million, as of September 30, 2017​.  Full Article

Heat Biologics Inc files for mixed shelf of up to $50 million ‍​
Monday, 30 Oct 2017 10:21am EDT 

Oct 30 (Reuters) - Heat Biologics Inc :Heat Biologics Inc files for mixed shelf of up to $50 million – SEC filing ‍​.  Full Article

SELEXIS SA AND PELICAN THERAPEUTICS SIGN AGREEMENT TO ADVANCE PELICAN’S IMMUNOTHERAPY CLINICAL PROGRAMS
Wednesday, 4 Oct 2017 08:00am EDT 

Oct 4 (Reuters) - Selexis SA::SELEXIS SA AND PELICAN THERAPEUTICS SIGN AGREEMENT TO ADVANCE PELICAN’S IMMUNOTHERAPY CLINICAL PROGRAMS.SELEXIS SA - CO, PELICAN THERAPEUTICS ENTERED INTO SERVICE AGREEMENT TO ADVANCE DEVELOPMENT OF PELICAN'S PROPRIETARY IMMUNOTHERAPY CLINICAL CANDIDATES.  Full Article

Heat Biologics says unit of co entered into a manufacturing agreement with KBI Biopharma
Wednesday, 27 Sep 2017 07:28am EDT 

Sept 27 (Reuters) - Heat Biologics Inc ::Heat Biologics Inc - on September 27, 2017, unit of co entered into a manufacturing agreement with KBI Biopharma -SEC filing.Heat Biologics- manufacturing agreement for cGMP production of its PTX-35 antibody and PTX-15 fusion protein.  Full Article

Heat Biologics been granted type C meeting with FDA
Tuesday, 12 Sep 2017 07:40am EDT 

Sept 12 (Reuters) - Heat Biologics Inc ::Heat Biologics- ‍been granted type C meeting with FDA; to discuss registrational pathway for non-small cell lung cancer trial with HS-110 in combination with Bristol Myers' opdivo.  Full Article

Heat Biologics says net loss for Q1 of 2017 was $3.2 million
Thursday, 11 May 2017 07:33am EDT 

May 11 (Reuters) - Heat Biologics Inc : :Says Net Loss for Q1 of 2017 was $3.2 million.Says Q1 loss per share $0.12.Q1 revenue $24,000.  Full Article

BRIEF-Heat Biologics Files For Offering Of Up To $15 Mln Of Its Common Stock

* FILES FOR OFFERING OF UP TO $15 MILLION OF ITS COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2GFwyfW) Further company coverage: